The emergence of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable buzz within the medical community. This groundbreaking dual GIP and GLP-1 target medication suggests to provide notable improvements in body loss compared to current therapies. Initial research trials have indicated